Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Women's use of Rogaine Extra Strength not a health risk, FDA advisory committee says.

This article was originally published in The Tan Sheet

Executive Summary

ROGAINE EXTRA STRENGTH FOR MEN WILL ATTRACT FEMALE BUYERS in spite of proposed labeling that states that the anti-baldness treatment is "not for use by women," FDA's Nonprescription Drugs and Dermatologic & Ophthalmic Drugs Advisory Committees predicted at a July 16 joint meeting in Bethesda, Md. Sixteen committee members voted "yes" and two "no" to the question of whether a "substantial number of women" would disregard the label statement and purchase the 5% minoxidil product, which awaits OTC approval.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel